» Articles » PMID: 33545455

Comparison of Abbott ID NOW COVID-19 Rapid Molecular Assay to Cepheid Xpert Xpress SARS-CoV-2 Assay in Dry Nasal Swabs

Overview
Date 2021 Feb 5
PMID 33545455
Citations 10
Authors
Affiliations
Soon will be listed here.
Citing Articles

Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients.

Colagrossi L, Costabile V, Scutari R, Cento V, Coltella L, Reale A Front Microbiol. 2022; 13:999783.

PMID: 36406396 PMC: 9670180. DOI: 10.3389/fmicb.2022.999783.


FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances.

Bruijns B, Folkertsma L, Tiggelaar R Biosens Bioelectron X. 2022; 11:100158.

PMID: 35619623 PMC: 9122839. DOI: 10.1016/j.biosx.2022.100158.


Evaluating the Ability to ID (COVID-19) NOW: a Large Real-World Prospective Evaluation of the Abbott ID NOW COVID-19 Assay.

Barker K, Small L, Thai D, Sohn K, Rosella L Microbiol Spectr. 2022; 10(3):e0051322.

PMID: 35579469 PMC: 9241745. DOI: 10.1128/spectrum.00513-22.


Comparison between nucleic acid amplification tests, antigen immunofluorescence assay, and in vitro infectivity in SARS-CoV-2 diagnosis.

Zupin L, Fontana F, Clemente L, Ruscio M, Crovella S Braz J Microbiol. 2022; 53(3):1271-1277.

PMID: 35446012 PMC: 9022615. DOI: 10.1007/s42770-022-00758-6.


Implementation of the Abbott ID Now COVID-19 assay at a tertiary care center: a prospective pragmatic implementation study during the third wave of SARS-CoV-2 in Ontario.

Deslandes V, Clark E, Thiruganasambandamoorthy V, Desjardins M Diagn Microbiol Infect Dis. 2021; 102(3):115609.

PMID: 34933188 PMC: 8626348. DOI: 10.1016/j.diagmicrobio.2021.115609.